Efficacy of weekly mizoribine pulse therapy in refractory lupus nephritis (Q47569278)

4 February 2018

title

Efficacy of weekly mizoribine pulse therapy in refractory lupus nephritis (English)

1 reference

4 February 2018

0 references

1 reference

13

Tsutomu Takeuchi

1 reference

4 February 2018

author name string

Eiko Nishi

1

1 reference

4 February 2018

Hideto Kameda

2

1 reference

4 February 2018

Hiroe Ogawa

3

1 reference

4 February 2018

Hayato Nagasawa

4

1 reference

4 February 2018

Hirofumi Takei

5

1 reference

4 February 2018

Ayumi Okuyama

6

1 reference

4 February 2018

Takahiko Kurasawa

7

1 reference

4 February 2018

Tsuneo Kondo

8

1 reference

4 February 2018

Koji Nishimura

9

1 reference

4 February 2018

Yuichiro Shirai

10

1 reference

4 February 2018

Ryota Sakai

11

1 reference

4 February 2018

Tatsuya Ito

12

1 reference

4 February 2018

Koichi Amano

14

1 reference

4 February 2018

publication date

22 April 2012

1 reference

4 February 2018

published in

Modern Rheumatology

1 reference

4 February 2018

volume

23

1 reference

4 February 2018

issue

1

1 reference

4 February 2018

page(s)

97-103

1 reference

4 February 2018

Revival of effective and safe high-dose mizoribine for the kidney transplantation.

cites work

2 references

https://api.crossref.org/works/10.3109%2FS10165-012-0645-6

21 January 2018

https://api.crossref.org/works/10.1007%2FS10165-012-0645-6

Evaluation of limited sampling designs to estimate maximal concentration and area under the curve of mizoribine in pediatric patients with renal disease.

21 January 2018

2 references

https://api.crossref.org/works/10.3109%2FS10165-012-0645-6

21 January 2018

https://api.crossref.org/works/10.1007%2FS10165-012-0645-6

Safety, tolerability and pharmacokinetics of higher-dose mizoribine in healthy male volunteers

21 January 2018

2 references

https://api.crossref.org/works/10.3109%2FS10165-012-0645-6

21 January 2018

https://api.crossref.org/works/10.1007%2FS10165-012-0645-6

Efficacy and safety of cyclosporine A in patients with refractory systemic lupus erythematosus in a daily clinical practice

21 January 2018

2 references

https://api.crossref.org/works/10.3109%2FS10165-012-0645-6

21 January 2018

https://api.crossref.org/works/10.1007%2FS10165-012-0645-6

Single center prospective study of tacrolimus efficacy and safety in the treatment of various manifestations in systemic lupus erythematosus

21 January 2018

2 references

https://api.crossref.org/works/10.3109%2FS10165-012-0645-6

21 January 2018

https://api.crossref.org/works/10.1007%2FS10165-012-0645-6

Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10165-012-0645-6

Sequential therapies for proliferative lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10165-012-0645-6

Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10165-012-0645-6

Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10165-012-0645-6

Guanine ribonucleotide depletion inhibits T cell activation. Mechanism of action of the immunosuppressive drug mizoribine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10165-012-0645-6

Functional interaction of the immunosuppressant mizoribine with the 14-3-3 protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10165-012-0645-6

Mizoribine intermittent pulse protocol for induction therapy for systemic lupus erythematosus in children: an open-label pilot study with five newly diagnosed patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10165-012-0645-6

Successful treatment of class V+IV lupus nephritis with multitarget therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10165-012-0645-6

10.3109/S10165-012-0645-6

21 January 2018

Identifiers

DOI

1 reference

4 February 2018

10.1007/S10165-012-0645-6

0 references

1 reference

4 February 2018